GlassScriptPhysician profile
Paul A Delyria
NPI 1457690125
$5,367.97
in general payments reported to CMS, 2019-2025
33 companies · $955 in 2025
The $955 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $383 · 2021: $703 · 2022: $671 · 2023: $913 · 2024: $1,318 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.13 |
| Education | $100.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $965.08 | 2019-2025 | Tavneos, Aranesp, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $919.62 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Otsuka America Pharmaceutical, INC. | $559.90 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $310.69 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $247.44 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $229.93 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $181.96 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $179.73 | 2019-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $178.13 | 2020-2025 | Terlivaz, Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $175.36 | 2021-2025 | |
| Akebia Therapeutics INC | $173.62 | 2019-2024 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.45 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $147.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $122.23 | 2021-2025 | Benlysta |
| Vifor Pharma, INC. | $88.88 | 2020-2024 | Veltassa, Korsuva |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $85.99 | 2019-2023 | Ultomiris |
| Daiichi Sankyo INC. | $78.69 | 2020-2024 | Injectafer |
| Genzyme Corporation | $60.87 | 2019-2023 | |
| Lilly USA, LLC | $56.56 | 2024 | Jardiance |
| Fresenius USA Marketing, INC. | $55.57 | 2022-2025 | Velphoro |
| Horizon Therapeutics Plc | $53.56 | 2020-2021 | |
| Genentech USA, INC. | $53.04 | 2019-2025 | Gazyva |
| Ani Pharmaceuticals, INC. | $40.56 | 2024-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $32.31 | 2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $26.45 | 2022 | |
| Outset Medical INC | $26.29 | 2019 | |
| Recordati_rare_diseases_inc. | $25.30 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $24.25 | 2019 | |
| Kyowa Kirin, INC. | $23.70 | 2025 | |
| Mallinckrodt Enterprises LLC | $22.73 | 2019 | |
| Scpharmaceuticals INC. | $22.39 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $18.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Delyria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.